Giving Life to Science®

We're advancing scientific breakthroughs to patients. Our R&D engine has yielded new medicines for devastating diseases including inflammatory, fibrotic & immunological conditions, intractable cancers & lymphatic, neurological & GI disorders

Focus on the Brain Immune Gut (BIG) Axis

25 therapeutics and therapeutic candidates

17 are clinical stage

2 granted FDA clearance & European marketing authorization

Relationships with leading pharma companies or their investment arms

Team of world-class scientists and industry leaders

PureTech's Components of Value


Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs*
Phase 1
Phase 2
Phase 3
Idiopathic pulmonary fibrosis (IPF)
Long COVID2 respiratory complications & related sequelae
Lymphatic flow disorders, including lymphedema
Anti-Galectin-9 MAb
Solid tumors
Anti-Delta-1 MAb
Solid tumors
Oral Allopregnanolone
Neurological indications
Oral IL-22 +
(Imbrium collaboration) Non-opioid
Phase completedPhase in progressRegistration-enabling studies to begin in 1H2022

Cash at Parent Level

Founded Entities

Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Science: The Gut’s Clostridium Cocktail
Press releases
PureTech to Present at the UBS Global Healthcare Conference
Press releases
PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022
Press releases
PureTech Announces Share Buyback Programme Update

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS).

3 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations such as those with Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Calculated as of January 1, 2017 to June 30, 2021. 

4 This represents a non-IFRS measure used by management for planning and reporting purposes. Please see below for a reconciliation of this measure to consolidated cash and cash equivalents, which is the most directly comparable measure calculated in accordance with IFRS:

PureTech Level Cash and Cash Equivalents is an alternative performance measure which is adjusted and constitutes a non-IFRS measure. We believe that these non-IFRS performance measures, when provided in combination with IFRS measures, will provide investors, analysts and other stakeholders with helpful complementary information to better understand our financial position from period to period. The measures are not substitutable for IFRS measures and should not be considered superior to measures presented in accordance with IFRS. These figures are unaudited and do not present all information necessary for an understanding of the Company’s financial condition as of September 30, 2021.